Cargando…

Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis

BACKGROUND: Previous studies demonstrated substantial economic and comorbidity burden associated with psoriasis (PsO) before biologics were available. Biologics have changed PsO treatment paradigms and potentially improved patient outcomes. There is a need to reassess the economic and comorbidity bu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feldman, Steven R., Zhao, Yang, Shi, Lizheng, Tran, Mary Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397856/ https://www.ncbi.nlm.nih.gov/pubmed/26402388 http://dx.doi.org/10.18553/jmcp.2015.21.10.874

Ejemplares similares

Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis
por: Feldman, Steven R., et al.
Publicado: (2015)

Economic Burden of Comorbidities in Patients with Psoriasis in the USA
por: Wu, Jashin J., et al.
Publicado: (2022)

Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database
por: Feldman, Steven R., et al.
Publicado: (2017)

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
por: Jiang, Yuxiong, et al.
Publicado: (2023)

Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2015)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
por: Lopes, Nilcéia, et al.
Publicado: (2019)

The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey
por: Girolomoni, Giampiero, et al.
Publicado: (2020)

Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
por: Barker, Jonathan, et al.
Publicado: (2021)

Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study
por: Narayanan, Siva, et al.
Publicado: (2014)

Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis
por: Choi, Chong Won, et al.
Publicado: (2018)

Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population
por: Lee, Seina, et al.
Publicado: (2018)

Psoriasis Causes Significant Economic Burden to Patients
por: Mustonen, A., et al.
Publicado: (2014)

Economic Burden of COPD in the Presence of Comorbidities
por: Mannino, David M., et al.
Publicado: (2015)

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
por: Thatiparthi, Akshitha, et al.
Publicado: (2021)

Therapy of moderate and severe psoriasis
por: Claes, Christa, et al.
Publicado: (2006)

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
por: Feldman, Steven R., et al.
Publicado: (2018)

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
por: Mantovani, Lorenzo, et al.
Publicado: (2016)

The Humanistic and Economic Burden Associated with Anxiety and Depression among Adults with Comorbid Diabetes and Hypertension
por: Wallace, Kimberly, et al.
Publicado: (2018)

Psoriasis: Comorbidities
por: Yamazaki, Fumikazu
Publicado: (2021)

A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
por: Salgado-Boquete, Laura, et al.
Publicado: (2021)

Treatment Approaches to Moderate to Severe Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2017)

Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study
por: Nguyen, Hao Trong, et al.
Publicado: (2023)

Economic burden of comorbid chronic conditions among survivors of stroke in China: 10-year longitudinal study
por: Zhang, Ji, et al.
Publicado: (2021)

Whether New Cooperative Medical Schemes Reduce the Economic Burden of Chronic Disease in Rural China
por: Jing, Shanshan, et al.
Publicado: (2013)

Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States
por: Enos, Clinton W., et al.
Publicado: (2021)

Psoriasis: new comorbidities
por: Machado-Pinto, Jackson, et al.
Publicado: (2016)

Comorbidity in Men with Psoriasis
por: Salihbegovic, Eldina Malkic, et al.
Publicado: (2021)

Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries
por: Tack, Jan, et al.
Publicado: (2019)

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
por: Hendrix, Nathaniel, et al.
Publicado: (2018)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

Epidemiology of psoriasis in Italy: burden, cost, comorbidities and patients’ satisfaction. A systematic review
por: Gianfredi, Vincenza, et al.
Publicado: (2022)

Economic burden of adult patients with β-thalassaemia major in mainland China
por: Zhen, Xuemei, et al.
Publicado: (2023)

A Systematic Review of the Direct Economic Burden of Type 2 Diabetes in China
por: Hu, Huimei, et al.
Publicado: (2015)

Bounded integer model‐based analysis of psoriasis area and severity index in patients with moderate‐to‐severe plaque psoriasis receiving BI 730357
por: Ooi, Qing Xi, et al.
Publicado: (2023)

The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease
por: Hong, Yoon Duk, et al.
Publicado: (2020)

Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007)

Biological therapies in moderate and severe psoriasis: perspectives and certainties
por: Constantin, MM, et al.
Publicado: (2014)

THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS: A BIOLOGIC REVOLUTION
por: Skillen, LA, et al.
Publicado: (2018)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nk752mermj8u5pnk3dti9cu8ku